The anthracycline antibiotics play a prominent role in the treatment of leukaemia and solid tumours in humans. Among this class of compounds, doxorubicin has shown significant activity against a wide range of human cancers, including leukaemia, lymphomas and a variety of solid tumours (Tan et al., 1973; Frederickson et al., 1974) . Unfortunately, the clinical use ofthe agent is limited by an unusual cardiomyopathy, which is related to the total cumulative dose of the drug (Minow et al., 1977) . Doxorubicin also produces acute toxicity in the form of bone marrow depression, alopecia and oral ulceration (O'Bryan et al., 1977) .
New formulations of doxorubicin using liposomes as delivery systems have been investigated to avoid treatmentlimiting side-effects and to achieve better therapeutic efficacy (Forsen and Tokes, 1981; Gabizon et al., 1982; Gregoriadis et al., 1974; Olson et al., 1982; Rahman et al., 1980) . Previously, our laboratory showed that encapsulation of doxorubicin into liposomes prepared from cardiolipin, egg phosphatidylcholine, cholesterol and stearylamine was less toxic than conventional doxorubicin in mice and beagle dogs (Herman et al., 1983; Rahman et al., 1985) . At the same time, liposome-encapsulated doxorubicin (LED) had equivalent or greater anti-tumour activity than conventional doxorubicin against various murine tumour models (Rahman et al., 1986a) . Subsequently, LED was used for the phase I and phase II clinical trials Treat et al., 1990) . LED was found to be well tolerated and demonstrated significant anti-tumour activity in patients with recurrent breast cancer . Intraperitoneally administered LED was also found to be safe and effective in patients with ovarian cancer (Delgado et al., 1989) .
Despite the encouraging clinical results observed in patients, further studies with LED could not be carried out primarily because of the problems related to the successful scale-up of the liposomes. Also the entrapment of doxorubicin into these liposomes was low (45-55%), requiring time-consuming processes to remove the unentrapped doxorubicin. Therefore, in order to improve the entrapment efficiency, we changed the liposome composition as well as substituting natural cardiolipin with synthetic tetramyristoyl cardiolipin. As the chemical composition, charge, structure and mode of preparation are all known variables that can modify the physicochemical, biological and pharmacological properties of the liposomes and therefore of the encapsulated drug, the present study was undertaken to evaluate the new liposomal doxorubicin formulation for its modulation of multidrug resistance, safety, efficacy and pharmacokinetic behaviour in animals.
Materials and methods

Chemicals
Doxorubicin was purchased from Adria Laboratories (Columbus, OH, USA) and egg phosphatidylcholine and cholesterol from Avanti Polar Lipids (Alabaster, AL, USA). 1,1 ',2,2'-Tetramyristoyl cardiolipin, synthesised by Avanti Polar Lipids was a generous gift. All other chemicals were reagent grade.
Animals
Male CD2F1 mice and female DBA/2 mice, 8-10 weeks old, 20-25 g were purchased from the National Cancer Institute (Frederick, MD, USA). Mice were maintained according to accredited procedures in our facility, and fed purina chow and water ad libitum. HL-60 promyelocytic leukaemic cells were obtained from the American Type Culture Collection (Rockville, MD, USA). The vincristine-resistant subline HL-60/VCR (obtained from Dr Melvin Center), which expresses the multidrug resistance phenotype was maintained in suspension culture with 2,M vincristine (McGrath and Center, 1988) . Cultures were grown as suspensions in RPMI-1640 medium (Gibco Laboratories, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine and penicillin/streptomycin. Cell lines were maintained at 37°C under 95% relative humidity in an atmosphere containing 5% carbon dioxide. The vincristine-resistant subline was maintained in drug-free medium for at least 1 week before study.
Preparation of liposomes 1,1',2,2'-Tetramyristoyl cardiolipin, phosphatidylcholine and cholesterol in a molar ratio of 1:10:6.8 were dissolved in chloroform-methanol (2:1) mixture and dried in a rotating flask under vacuum. Doxorubicin (1 mg ml-1), in sterile normal saline was added to the dried lipid film. The drug to lipid molar ratio was 1:10. The film was hydrated and dispersed by vigorous vortexing. The hydrated suspension was sonicated for 30 min in a bath type sonicator (Heat Systems, W380) to yield small unilamellar liposomes. In separate experiments, lipids were lyophilised and doxorubicin in saline was added. The mixture was allowed to hydrate for 1 h and then sonicated to obtain small unilamellar liposomes. The unincorporated doxorubicin was separated from liposomally entrapped drug by extensive dialysis against sterile normal saline at 4°C over a period of 20 h or by gel chromatography using Sephadex G-50. The amount of doxorubicin encapsulated in liposomes was determined by fluorescence measurement (470 nm, excitation; 580 nm, emission). In all the experiments, the concentration of doxorubicin encapsulated in liposome was equivalent to the concentration of free drug used. The size of the liposomes as determined by flow cytometry was found to be less than 0.5 ,um. Blank liposomes were prepared using the same composition of lipids in the absence of doxorubicin; they were diluted in sterile saline to yield lipid doses equivalent to those of liposome-encapsulated doxorubicin.
Cytotoxicity assay
The growth-inhibition method was used to determine the cytotoxicity of conventional doxorubicin and LED in human promyelocytic leukaemia cells. In brief, 5 x 104 HL-60 and HL-60/VCR cells were plated in tissue culture cell wells (well diameter 35 mm, Corning, NY, USA). Cells in exponential growth were exposed to varying concentrations of doxorubicin or LED for 72 h at 37°C. Cells were then counted in a haemocytometer, and viability was determined by trypan blue dye exclusion. The data is expressed in terms of IC50, which corresponds to the concentration of the drug resulting in 50% survival of the cells compared with control.
Toxicity evaluation For the comparison of lethal toxicity of conventional doxorubicin and LED, normal CD2F1 male mice received single i.v. doses of 15, 20 and 25 mg kg-'. The mice were observed until day 60 after drug administration. The control mice received either saline or blank liposomes representing the same concentration of the lipid as was used to entrap a dose of 25.0 mg kg-' doxorubicin. Mice in each group were weighed and observed daily.
In vivo antitumour activity study For in vivo anti-tumour studies, male CD2F1 mice were injected i.p. on day 0 with 1 x 105 viable L1210 leukaemia cells. On day 1, they were randomly divided into groups of ten mice. Each group received varying doses of either conventional doxorubicin or LED administered i.p. Control groups received saline or blank liposomes i.p. The injection volume was 2% body weight (0.2 ml 10 g-' body weight).
Survival was recorded every 24 h and the mice were evaluated until day 60.
Pharmacological disposition studies For pharmacological studies, male CD2F1 mice were injected i.v. via the tail vein with 6 mg kg-1 of either conventional doxorubicin or LED. At 5 min, 15 min, 1 h, 2 h, 4 h, 8 h and 24 h after drug administration, four mice in each group were bled from the retro-orbital sinus into heparinised tubes and were killed by cervical dislocation. The blood was centrifuged at 2000 r.p.m. for 10 min at 4°C to separate the plasma. The liver, spleen, kidney, lung, heart and small intestine were rapidly excised and rinsed in ice-cold normal saline. The organs and plasma were frozen at -20°C until assayed for doxorubicin.
Plasma and tissue samples were analysed for doxorubicin by the method as pseviously described (Rahman et al., 1986b) . Plasma (0.25 ml) was diluted to 1 ml with distilled water, followed by addition of 0.2 ml of silver nitrate (33%, w/v). Tissues were homogenised in 1 ml of distilled water in a Polytron homogeniser (Brinkmann Instruments, Westbury, NY, USA) followed by addition of 0.2 ml of silver nitrate. The tubes were vortexed and 3 ml of n-butyl alcohol saturated with water was added. Each tube was vortexed vigorously for 1 min and then centrifuged at 5000 r.p.m. for 10 min. The organic layer was removed followed by further extraction of residue with 2 ml of n-butyl alcohol. The two extracts were pooled and doxorubicin was assayed spectrofluorometrically at 470 nm excitation and 580 nm emission. Control plasma and tissue samples obtained from mice treated with normal saline or blank liposomes were processed similarly to correct for any endogenous fluorescence. Standards were prepared by spiking known concentrations of doxorubicin in blank plasma and tissue to calculate the concentration of doxorubicin in samples.
Plasma pharmacokinetic parameters were assessed by standard methods (Gibaldi and Perrier, 1982 
Encapsulation efficiency of liposomes
The encapsulation of doxorubicin into liposomes prepared using phosphatidylcholine, cholesterol and 1,1',2,2'-tetramyr-istoyl cardiolipin by conventional methods, was found to be greater than 90% (n=20). In other experiments, lipids were lyophilised and then reconstituted with doxorubicin solution in saline. In all these experiments, more than 90% encapsulation of doxorubicin was also observed (n=20).
In vitro cytotoxicity The concentration of conventional doxorubicin that caused 50% growth inhibition (IC50) in the parent HL-60 cells after 3 days of exposure was 10.5 ng ml-', whereas it was 0.412 ,ug ml-1 in HL-60/VCR cells. Hence, HL-60/VCR cells with multidrug resistance phenotype were 39-fold resistant to doxorubicin. When liposomal doxorubicin was used, the IC50 for HL-60 cells was 7.5 ng ml-', which was similar to conventional doxorubicin. However, liposomal doxorubicin showed a 4.7-fold potentiation in cytotoxicity to HL-60/VCR cells compared with conventional doxorubicin (P<0.001); the IC50 being 0.088 jug ml-1 (Figure 1) In vivo activity To determine the anti-tumour activity of doxorubicin entrapped in liposomes, studies were carried out against the murine L1210 ascitic leukaemia in CD2F1 mice (Figure 2 *P<0 001.
Pharmacokinetics
The plasma pharmacokinetics of conventional doxorubicin and liposome-encapsulated doxorubicin in mice at a dose of 6 mg kg-1 is presented in Figure 3 . Following i.v. administration of conventional doxorubicin, the peak plasma concentration achieved was 0.867 pg ml-'. On the other hand, with liposomes, the peak plasma concentration of doxorubicin achieved was 38.04 pg ml-', which was 43.8 times more than conventional doxorubicin. The comparative pharmacokinetic parameters obtained after a single i.v. bolus administration of conventional doxorubicin and doxorubicin entrapped in liposomes are presented in Table II (Biedler and Riehm, 1970; Dano, 1973) . This type of MDR has been related to overamplification of a gene, mdrl, and its overexprssed gene product, p-glycoprotein, in auncer cells (Juliano and Ling, 1976; Kartner et al., 1985; Morrow and Cowan, 1988) . The p-glycoprotein has been shown to function as an efflux pump that prevents accumulation of drugs and alters their cytotoxicity in cancer cells (Gottesman and Pastan, 1988; Horio et al., 1988) . Recently, extensive studies from our laboratory have demonstrated that liposome-encapsulated doxorubicin effectively modulates the MDR phenotype in cancer cells by altering the function of p-glycoprotein. The liposomes were shown to bind specifically to p-glycoprotein, which was demonstrated by inhibiting the photoaffinity labelling of azidopine to the p-glycoprotein. This binding was associated with enhanced cellular drug accumulation and altered drug distribution inside the MDR-expressing cells (Thierry et al., 1989; Oudard et al., 1991; Rahman et al., 1992; Thierry et al., 1993) . The modulation of MDR phenotype by liposomes has been shown in vitro in a number of human cancer cell lines (Thierry et al., 1989; Oudard et al., 1991; Rabman et al., 1992; Thierry et al., 1993) and in vivo in transgenic mice (Mickisch et al., 1992) transfected with a functional human mdrl gene. The present study demonstrates that LED modulates multidrug resistance in HL-60/VCR cells and this modality of treatment enhances the cytotoxicity nearly 5-fold as compared with conventional doxorubicin. These observations support the hypothesis that substitution of natural cardiolipin with synthetic cardiolipin maintains the capacity of liposomes to modulate MDR.
The goal of using liposomes as a drug-delivery system involves a high concentration and/or long duration of action at a target site, where beneficial effects may occur while maintaining a low concentration and/or reduced duration at other sites, where adverse effects may occur.
Such an objective requires altering the organ distnbution of the drug substantially. Much of the work on liposomes has been focused on cancer treatment as conventional cancer therapy has been far from satisfactory. Liposomes encapsulating a variety of anti-cancer agents have been shown to enhance anti-tumour activity, decrease toxicity and alter in vivo tissue distribution (Kim, 1993) . In the present study, doxorubicin encapsulated in liposomes prepared from phosphatidylcholine, cholesterol and synthetic cardiolipin was found to significantly alter the specific tissue distribution of the drug in mice as compared with conventional drug. These altered disposition characteristics were found to be associated with significant reduction in the lethal toxicity of liposome-encapsulated doxorubicin. The concentration of drug in cardiac tissue was at least 2-fold lower following administration of LED compared with conventional doxorubicin. LED was also found to be more effective in the treatment of the murine L1210 leukaemia model. In summary, this study demonstrates that the new liposomal formulation with synthetic cardiolipin as its integral component is beneficial for overcoming multidrug resistance and provides enhanced therapeutic advantages over conventional doxorubicin. We believe that these preclinical findings support evaluation of this LED preparation in clinical trials.
